Evidence map›Paper›PMID 27328849›Full record

ArticleNature communications2016

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.

Peter Ulz, Jelena Belic, Ricarda Graf, Martina Auer, Ingrid Lafer, Katja Fischereder, Gerald Webersinke, Karl Pummer, Herbert Augustin, Martin Pichler and 5 more

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03677414 unknown statusnot on this mapstarted 2018, after this paper: background citation

Analysis of Androgene Receptors Axis and DNA Damage Repair Genes From Plasma DNA (ctDNA) in Patients With Prostate Cancer

TypeobservationalSponsorMedical University of GrazRan2018 to 2021Enrolled59ConditionsProstatic Neoplasms
NCT03992521 unknown statusnot on this mapstarted 2018, after this paper: background citation

Breast Cancer Liquid Biopsy Stratification

TypeobservationalSponsorMedical University of GrazRan2018 to 2023Enrolled59ConditionsBreast CancerArmsNucleosome positioning
NCT04015622 phase2active not recruitingnot on this mapstarted 2020, after this paper: background citation

A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2020 to 2026Enrolled100ConditionsMetastatic Castration-Resistant Prostate Cancer (mCRPC)ArmsEnzalutamide, Docetaxel
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Peter UlzInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.ORCID 0000-0001-5941-1160
Jelena BelicInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Ricarda GrafInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Martina AuerInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Ingrid LaferInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Katja FischerederDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria.
Gerald WebersinkeDepartment of Internal Medicine I, Hospital Barmherzige Schwestern Linz, A-4020 Linz, Austria.
Karl PummerDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria.
Herbert AugustinDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria.
Martin PichlerDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, A-8036 Graz, Austria.
Gerald HoeflerInstitute of Pathology, Medical University of Graz, A-8036 Graz, Austria.
Thomas BauernhoferDepartment of Internal Medicine, Division of Oncology, Medical University of Graz, A-8036 Graz, Austria.
Jochen B GeiglInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Ellen HeitzerInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.
Michael R SpeicherInstitute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria.ORCID 0000-0003-0105-955X
Medical University of Graz · ATOrdensklinikum Linz Barmherzige Schwestern · AT

Funding

Austrian Science Fund FWF P 23284Austrian Science Fund FWF W 1226
6 · The paper itself

Abstract

Genomic alterations in metastatic prostate cancer remain incompletely characterized. Here we analyse 493 prostate cancer cases from the TCGA database and perform whole-genome plasma sequencing on 95 plasma samples derived from 43 patients with metastatic prostate cancer. From these samples, we identify established driver aberrations in a cancer-related gene in nearly all cases (97.7%), including driver gene fusions (TMPRSS2:ERG), driver focal deletions (PTEN, RYBP and SHQ1) and driver amplifications (AR and MYC). In serial plasma analyses, we observe changes in focal amplifications in 40% of cases. The mean time interval between new amplifications was 26.4 weeks (range: 5-52 weeks), suggesting that they represent rapid adaptations to selection pressure. An increase in neuron-specific enolase is accompanied by clonal pattern changes in the tumour genome, most consistent with subclonal diversification of the tumour. Our findings suggest a high plasticity of prostate cancer genomes with newly occurring focal amplifications as a driving force in progression.

Indexed as

Chromosome AberrationsGenome, HumanBiopsyCell DifferentiationCluster AnalysisDisease ProgressionDNA, NeoplasmGene DeletionGene DosageHumansMaleNeoplasm MetastasisProstate-Specific AntigenProstatic NeoplasmsProto-Oncogene Proteins c-mycSequence Analysis, DNADNA, NeoplasmMYC protein, humanProstate-Specific AntigenProto-Oncogene Proteins c-myc

Identifiers

PMID27328849
PMCPMC4917969
OpenAlexW2472811390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.